Group items tagged

The Community Pharmacy England (CPE) has called the recent announcement of six per cent pay rise for the public sector workforce as 'unfair' for the community pharmacy sector. On Thursday (13 June), the Department of Health and Social Care (DHSC) announced that pay scales for most doctors and dentists will increase by at least a six per cent this year after the government accepted the recommendations from the independent pay review bodies in full. Responding to the recent announcement Chief Executive Janet Morrison, said: "The public sector workforce pay rise will be welcome news for its recipients given the huge inflationary pressures and the ongoing impact of the cost-of-living crisis. But for community pharmacy owners - who have faced 30% funding cuts in recent years and who are struggling to meet their rising wage costs - this feels unfair, and very far from good news. At Community Pharmacy England we are fully focused on the current financial and operational pressures and fighting hard for a sustainable long-term funding arrangement.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

Alitam has announced that it has merged with clinical skills training provider MHRx to upskill UK pharmacists so that its chain of community pharmacies in the UK can diagnose and treat minor medical ailments "quickly and safely". This is a second merger deal announced by the group that has 100-plus pharmacies, just days after its merger with Pharmadoctor to "radically transform the UK and Ireland's community pharmacy sector" into a truly preventative healthcare system. Following the merger with MHRx, Alitam will now be providing a career development platform for its pharmacy teams, which also include nurses and other healthcare professionals. MHRx's training incorporates every aspect of general practice alongside relevant topics including making appropriate patient consultation records in line with NHS guidelines. This, Alitam believes, will allow community pharmacies to carry out formal diagnoses, formulate differential diagnosis plans, and perform full clinical examinations. According to the founder and CEO Feisal Nahaboo, mergers such as these will lead to "a healthcare revolution predicated on building the world's first truly preventative healthcare model".

The Competition and Markets Authority (CMA) has announced on Tuesday (20 June) that it may consider undertakings offered by Bestway Panacea Holdings, a parent company of Well Pharmacy, which involves divesting seven pharmacy stores under the merger deal with Lexon UK. The Authority said: "CMA considers that there are reasonable grounds for believing that the undertakings offered by Bestway, or a modified version of them, might be accepted by the CMA under the Enterprise Act 2002." Last week, the Authority had announced that the merger of Bestway, and independent pharmacy owner Lexon UK could "lessen the competition between retail pharmacies" in England. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal.

All adults aged 50 years and above are eligible for free flu jabs in England under the autumn Covid-19 booster programme, the Department of Health and Social Care (DHSC) has announced. "The flu virus could also be highly infectious at this time of year, so I am also announcing that those eligible for a free flu vaccination this year will include everyone aged 50 and over, primary school children and secondary school pupils in years 7, 8 and 9, as well as people in clinical risk groups, unpaid carers and household contacts of those who are immunosuppressed," said new health secretary Steve Barclay. Commenting on the DHSC's announcement, CCA chief executive Malcolm Harrison said: "We welcome the decision to accept the advice of the JCVI on who can have free Covid-19 boosters and flu jabs this autumn. Community pharmacies have turbo-charged the Covid-19 vaccination programme over the past 18 months and last year we witnessed the most successful community pharmacy flu campaign ever."

Lloyds Pharmacy announced the withdrawal of pharmacy services from all Sainsbury's stores over mounting "industry pressures" faced by the community pharmacies. The company had 77 branches at the beginning of this year - out of which five branches closed their doors and transferred the ownership of the remaining 72 to others. It was announced in June this year that Lloyds Pharmacy branches in Sainsbury's will close its operation throughout 2023. The following decision came after "changing market conditions" put 2,000 jobs on the line across the UK. Four Lloyds Pharmacies inside Wales Sainsbury's stores closed within days of the announcement and one in the Roath suburb of Cardiff as well. The remaining 72 changed hands as confirmed by the figures obtained by WalesOnline on 5 October.

The Pharmacists Defence Association (PDA) has expressed its interest to support pharmacists impacted with the latest announcement of the closure of Tesco pharmacies. "Tesco have followed ASDA and LloydsPharmacy (at Sainsbury's) to announce cost cutting changes to their stores, impacting hundreds of jobs," the association said. The PDA's interests in the announcement relate to the planned closure of eight in-store Tesco pharmacies and the impact of those closures upon pharmacists, however the union is of course concerned for all those impacted. The PDA Union will support individual PDA members impacted by the decision so that they are aware of, and can exercise, their rights at work in relation to this situation. Paul Day, PDA Union Director said, "In addition to the immediate impact on pharmacists employed at the stores marked for closure, this is the third instance in just twelve days of reductions in the overall access to a pharmacy for NHS patients. We expect those who represent communities to be concerned about the loss of a key part of their local NHS service."

The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK. Through this funding, the government aims to create the most advanced genomic healthcare system in the world. "Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a £175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC. The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA. "£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC. "An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information such as routine scans.

Within 24 hours of the Princess of Wales, Kate Middleton's, cancer diagnosis, National Health Service (NHS) England saw a 373% spike in visits to its cancer page, highlighting the growing focus on cancer awareness. Similarly, charities like Macmillan Cancer Support charity experienced increased traffic, with nearly 100,000 visits to their support pages since the announcement. Traffic to the NHS website's cancer symptoms page surged significantly, recording a remarkable 4,172 visits within three hours of the release of the Princess's video message. This sudden increase translated to an average of one visit every three seconds, a substantial rise from the 1,922 visits recorded during the same timeframe a week earlier. Notably, visits to the symptoms page peaked immediately after the announcement, with 1,678 visits recorded between 6 pm and 7 pm on the day of the announcement.

To support NHS, clear the backlog created by the Covid-19 pandemic and help community pharmacies support more people, the Welsh government has announced an allocation of further £12.5 million funding. Of the total amount, £10mn will be distributed across the 22 local authorities to buy equipment to help people to live independently in their own homes post hospital stay. The remainder, £2.5mn, will be used to support community pharmacists and patients to improve access to treatment and advice for a range of common ailments. The move is aimed at alleviating waiting times and reducing winter pressures on the NHS. Commenting on the announcement, Elen Jones, Royal Pharmaceutical Society director for Wales said: "We are delighted that the Welsh government continue to recognise the value of pharmacists in patient care and we welcome this additional investment and support for Community Pharmacy teams across Wales.

Trainee pharmacists at Boots in England and Northern Ireland will get a pay increase from 1st August. The new pay rates agreed between the Pharmacists' Defence Association (PDA) Union and Boots was announced on Tuesday (4 July). The joint statement released by Boots and PDA Union said: "Following discussions, we are pleased to announce that there will be a pay increase for Trainee Pharmacists, in England and Northern Ireland, commencing in role this summer." Trainee Pharmacists working in Boots Pharmacies in Wales are employed directly by the NHS and are therefore outside the scope of the pay negotiations between Boots and the PDA Union. Funding for each Boots Trainee Pharmacist in Scotland is at a higher level and Boots continues to pass on the fully funded amount as salary to those team members

Community Pharmacy England (CPE) CEO, Janet Morrison said that the negotiations for the £645 million investment pledged to community pharmacies in 2023-25 have concluded. The government's primary care recovery plan is to be announced in a "few weeks" and negotiations for the Community Pharmacy Contractual Framework (CPCF) from April 2024 will begin. She said: "We have finished the substantive discussions on the recovery plan but detailed discussions about implementation are ongoing and we are awaiting final clearance from the Government and the NHS. "We hope that we will be in a position to make an announcement in the next few weeks and that negotiations on the CPCF from April 2024 will commence soon after that." Morrison reminded attendees that the Primary Care Recovery Plan is "to improve access to primary care by investing £645 million over the remainder of the year".

GrowLife has announced that Organic Growth International, its previously announced joint venture with CANX USA, has entered into a series of agreements with CEN Biotech, subject to the approval of the GrowLife board of directors.

Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.

As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move. The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six months after their second dose, and that 16 and 17 year olds should be invited to have a second dose. Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice. "We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted the following price concessions for November 2021. Contractors can find information on the price concessions and learn about the process involved on PSNC's website. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHSBSA to all items submitted for payment in the same month for which a price concession is granted. PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated November 2021 Drug Tariff price.

Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27). In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work. From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily. Besides, the legal mandate to wear face masks will go away from next week. Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign". He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose. "Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over". "I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."

An international specialty pharmaceutical group, Essential Pharma has announced the completion of two transactions with fellow UK-based Rosemont Pharmaceuticals. The company completed the divestment of its oral liquid portfolio to Rosemont, and acquired a series of attractive, niche products with "geographic expansion potential." Commenting on the announcement, Essential Pharma chief executive Steen Vangsgaard said: "The Rosemont products bring additional niche products into our portfolio with international expansion potential. "The divestiture of our UK oral liquid products streamlines our portfolio, allowing us to focus and accelerate our strategic growth ambition of building a leading international specialty pharma platform." Under the divestment deal, Rosemont Pharmaceuticals will acquire the product portfolio of licences, registrations and trademarks, as well as related commercial rights, to a number of oral generic products which are used to treat a range of conditions in various therapeutic areas.

Deviating from the initial schedule to kick off the flu and Covid-19 vaccination campaigns in October, the NHS England has announced that the autumn vaccination drive will commence sooner than expected in England, starting on September 11. This decision was taken as a precaution in response to a new Covid-19 variant. The precautionary measure is being taken as the Department of Health and Social Care and the UK Health Security Agency examined the variant BA.2.86, which was first detected in the UK on Friday, August 18, 2023, the NHSE said on Aug. 30. While NHS England had previously announced that vaccinations for both NHS programmes would begin on October 2 for residents of older adult care homes, appointments for other eligible groups were scheduled for the following week, starting on October 7. This decision prompted community pharmacy leaders to denounce the delayed start of the flu service as 'unacceptable'.

Boots pharmacists will receive a pay rise of 4.5 per cent as the pharmacy multiple and PDA Union jointly announce this year's pay settlement. Following discussions between Boots management services and the PDA Union negotiators, the agreement was reached in relation to this year's pay claim, effective from 1 November 2022. The union also announced that those who have already had a pay increase on or since 1 August 2022, where that increase has been less than 4.5 per cent, a 'top up' increase will be provided, from 1 November 2022, to ensure that all eligible members of the bargaining unit receive a pay increment of not less than 4.5 per cent in 2022. Boots and the PDA Union have agreed an increase to the pay of those above the maximum market range by 4 per cent with an additional 0.5 per cent non-consolidated payment.